Dementia and Alzheimer Disease

In recognition of National Public Health Week, held April 6-12, NeurologyLive summarizes recent literature showing that environmental exposures are associated with increased risk of neurologic disorders.

High-dose influenza vaccination was associated with a lower risk of incident Alzheimer dementia compared with standard-dose vaccination among adults aged 65 years and older in a large US claims-based cohort study.

Members from Danaher Diagnostics provided clinical commentary and insights on an emerging immunoassay geared towards testing apolipoprotein (APOE) in patients with suspected Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 3, 2026.

Adults with Down syndrome face a high lifetime risk of early-onset Alzheimer disease linked to the triplication of chromosome 21, driving ongoing clinical investigations into targeted biomarkers and therapies for this population.

Phase 2 findings indicated that the investigational agent zervimesine exhibited a favorable safety profile and may slow disease progression in patients with mild to moderate dementia with Lewy bodies.

In honor of Down Syndrome Awareness Day, neurologist Elizabeth Head, PhD, discusses neurologic comorbidities, biomarker advances, and emerging precision medicine approaches in Down syndrome–associated Alzheimer disease.

MRI-guided focused ultrasound steers IV gene therapy to mouse brains, lowering cortical tau—though hippocampal response stays absent.

Phase 1 data suggest plasma GFAP levels may correlate with cognitive outcomes in patients with Alzheimer disease treated with troculeucel, an investigational autologous NK-cell therapy.

Two phase 3 ADAGIO trials test Cobenfy for Alzheimer’s agitation, assessing muscarinic modulation safety and efficacy as a potential new dementia care option.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with AAN President Natalia Rost, MD, MPH. [LISTEN TIME: 16 minutes]

Neurology News Network for the week ending March 7, 2026. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 6, 2026.

Large-scale proteomic and transcriptomic analyses position the synaptic protein NRN1 as a resilience-linked therapeutic candidate in Alzheimer disease, though validation remains preclinical.

A Large cohort analysis of more than 159,000 adults found greater adherence to multiple healthy dietary patterns—particularly the DASH diet—was linked to a significantly lower risk of subjective cognitive decline in midlife.

The neurologist at LMU Munich University Hospital discussed newly published data supporting plasma brain-derived tau as a dynamic biomarker of infarct growth and treatment response in acute ischemic stroke. [WATCH TIME: 4 minutes]

Pilot trial finds low-dose lithium is safe in mild cognitive impairment, hints at memory benefits, and guides larger studies for Alzheimer prevention.

Neal K. Shah, CEO of CareYaya Health Technologies, discusses how the largest workforce in the US maintains the safety of patients with dementia at home while remaining underpaid and unrecognized.

R. Scott Turner, PhD, MD, director of the memory disorders program at MedStar Georgetown University Hospital, discussed the importance of investigating environmental risk factors in Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 27, 2026.

In honor of Black History Month, neurologist Na Tosha Gatson, MD, PhD, reflects on structural inequities in neuro-oncology and advancing equity through mentorship, trial design, and institutional policy.

Kyle Marden, MD, sports neurologist at Northwestern Medicine, discussed the growing role of sports neurologists and new data supporting the feasibility of quantitative pupillometry as part of a multimodal approach to concussion diagnosis and recovery tracking.

Bruce Ovbiagele, MD, MSc, MAS, MBA, founding president of the Society for Equity Neuroscience (SEQUINS) reflects on Black History Month, SEQUINS initiatives, and the policy and guideline reforms needed to advance brain health equity in 2026 and beyond.

Neal K. Shah, CEO of CareYaya Health Technologies, discussed how AI-powered caregiver training platforms like YayaGuide can personalize dementia care education for family caregivers.

Catch up on any of the neurology headlines you may have missed in January 2026, compiled into 1 place by the NeurologyLive® team.